Neglected disease, Rare disease, drug discovery, Donate Button iRND3 Home Page
Background large

Publications

On Mechanism of Actions:

Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases
Swinney, DC
Clin Pharmacol Ther. 2016 Jul 9. doi: 10.1002/cpt.422.PMID: 27393380

Glycogen Synthase Kinase 3β promotes endocytosis of transferrin in the African Trypanosome
Guyett, PJ, Xia S, Swinney, DC, Pollastri, MP, Mensa-Wilmot, K
ACS Infect Dis 10.1021/acsinfecdis.6b00077 (2016)

A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β.
Swinney ZT, Haubrich BA, Xia S, Ramesha C, Gomez SR, Guyett P, Mensa-Wilmot K, Swinney DC.
PLoS Negl Trop Dis. 2016 Mar 4;10(3):e0004506. doi: 10.1371/journal.pntd.0004506. eCollection 2016.

Enzyme activity assays for protein kinases: Strategies to identify active substrates.
Haubrich BA, Swinney DC.
Curr Drug Discov Technol. 2016 Jan 15.

Drug Discoveries and Molecular Mechanism of Action
David C. Swinney
Successful Drug Discovery, Wiley-VCH (2015)

Kinetics and Thermodynamics of Drug Binding
GM Keserü, DC Swinney ed
Wiley-VCH , Weinheim, Germany 2015

How medicines for rare diseases were discovered?
Swinney DC & Xia S.
Frontiers Med Chem 6, 987-1002(2014)

Collaboration for rare disease drug discovery research
Litterman NK, Rhee M, Swinney DC, Ekins S.
F1000Res. 3:261 (2014)

A study into the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands
Swinney DC, Beavis P, Chuang KT, Zheng Y, Lee I, Gee P, Deval J, Rotstein DM, Dioszegi M, Ravendran P, Zhang J, Sankuratri S, Kondru R, Vauquelin G.
Br J Pharmacol. 171:3364-3375 (2014)

The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance
JSelen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, Martinez MN, Lennernäs H, Wigal TL, Swinney DC, Polli JE, Serajuddin AT, Cook JA, Dressman JB.
Pharm Sci.103:3377-97 (2014)

The value of translational biomarkers to phenotypic assays
Swinney DC.
Frontiers Pharmacol 15:171(2014)

The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines
Swinney DC.
J Biomol Screen.18:1186-92 (2013)

Phenotypic vs. Target–based drug discovery for First-in-Class medicines
Swinney DC.
Clin Pharmacol Thera 93, 299-301 (2013)

Molecular Mechanism of Action (MMoA) in Drug Discovery
David C. Swinney
Annual Reports in Medicinal Chemistry 46, 301-317 (2011)

How were new Medicines Discovered?
David C. Swinney & Jason Anthony
Nature Reviews Drug Discovery 10, 507-519 (2011)

Influence of Drug Binding Kinetics on Pharmacodynamic Properties
David C. Swinney
Drug Discovery 7, 53-57 (2010)

Biochemical Mechanisms of Drug Action: What Does it Take for Success?
David C. Swinney
Nature Reviews Drug Discovery 3, 801-808 (2004)

The Role of Binding Kinetics in Therapeutically Useful Drug Action
David C. Swinney
Curr Opin Drug Disc Dev 12(1): 31-39 (2009)

Application of Binding Kinetics to Drug Discovery: Translation of Binding Mechanisms to Clinically Differentiated Therapeutic Responses
David C. Swinney
Pharm. Med. 22: 23-34 (2008)

Opportunities to Minimise Risk in Drug Discovery and Development
David C. Swinney
Exp. Opin. Drug Disc. Dev. 1:627-633 (2006)

Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice
David C. Swinney
Let. Drug Design Disc. 3, 569-574 (2006)

Biochemical Mechanisms of New Molecular Entities (NMEs) Approved by United States FDA During 2001-2004: Mechanisms Leading to Optimal Efficacy and Safety
David C. Swinney
Cur. Topics Med. Chem. 6, 461-478 (2006)

 Home